CA
NZ
UK
AU
IND
US
Ipsen is a mid-cap French biopharmaceutical company specializing in rare disease therapies and specialty care products. With aMarket Capitalisationof approximately €9.2bn (as of May 2026), Ipsen generates 45% of itsRevenuefrom the United States and 30% from Europe, with a strategic focus on oncology, neuroscience, …
The pharmaceutical industry’s commercial teams have long grappled with a paradox: despite annual marketing budgets exceeding $30bn in the U.S. alone, the average share of voice—a proxy for engagement—remains stubbornly low. Studies suggest that over 60% of healthcare professionals (HCPs) ignore generic outreach, while …
Bristol Myers Squibb (NYSE: BMY) is quietly evaluating Houston as the site for a $1bn manufacturing campus—a sign that Big Pharma is increasingly betting on the American South and Sun Belt for critical production capacity. The Generation Park district, a 1,700-acre mixed-use development northeast …
ImmunityBio Inc (NASDAQ: IMBY) has secured a Prescription Drug User Fee Act (PDUFA) target action date of August 11 for its supplementalBiologicsLicense Application (sBLA) seeking to expand Anktiva (N-803) to first-line non-muscle-invasive bladder cancer (NMIBC). The FDA’s acceptance of the filing in late May …
The TrumpRx platform—officially launched in February 2026—has quietly become the federal government’s most visible lever in the fight against escalating prescription drug costs. On Monday the White House added more than 600 generic medicines to the site, positioning it as a one-stop shop where …
Merck & Co. (NYSE: MRK) and Kelun-Biotech’s experimental antibody–drug conjugate sacituzumab tirumotecan (sac-TMT) has become the first globally successful phase 3 therapy in endometrial cancer, a malignancy where new systemicOptionsremain scarce. The TroFuse-005 study met both co-primary endpoints—overall survival (OS) and progression-free survival (PFS)—according …
The U.S. Food and Drug Administration’s decision on May 5th—announced jointly by Daiichi Sankyo Co. (TYO: 4568) and AstraZeneca plc (LSE: AZN)—marks the first time an antibody-drug conjugate has been approved for early-stage HER2-positive breast cancer in both the neoadjuvant (pre-surgery) and adjuvant (post-surgery) …
Roche (SIX: ROG) has taken a calculated step to broaden access to its antiviral flu treatment, Xofluza (baloxavir marboxil), by inking a voluntary licensing deal with the Geneva-based Medicines Patent Pool (MPP). The agreement—announced on May 18th, 2026—grants generic manufacturers in 129 low- and …
A First-in-Class Drug That Could Reshape Hypertension Treatment
Bristol Myers Squibb (NYSE: BMY) has vaulted to the front of the pharmaceutical industry’s AI adoption curve by signing a multi-year strategic agreement with Anthropic to deploy its Claude Enterprise platform across global workflows. The deal—unveiled on Wednesday—marks a decisive shift from fragmented, department-level …
Please wait processing your request...